Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg - linezolid is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. linezolid is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4)]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14)]. community-acquired pneumonia caused by streptococcus pneumoniae, including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14)]. complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by staphylococcus aureus (methicillin-susceptible and resistant isolates), streptococcus pyogenes , or streptococ

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

alembic pharmaceuticals limited - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg - linezolid tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. linezolid tablets are   not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14) ].  community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14) ]. complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococc

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

eugia us llc - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg in 300 ml - linezolid injection is indicated for the treatment of nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14)]. linezolid injection is indicated for the treatment of community-acquired pneumonia caused by streptococcus pneumoniae, including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14) ]. linezolid injection is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes, or streptococcus agalactiae. linezolid injection has not been studied in the treatment of decubitus ulcers [see   clinical studies (14) ]. linezolid is indicated for the treatment of uncomplicated skin and skin structure infections caused by staphylococcus aureus

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 200 mg in 100 ml - linezolid injection is indicated for the treatment of nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [ see clinical studies (14) ]. linezolid injection is indicated for the treatment of community-acquired pneumonia caused by streptococcus pneumoniae

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

hospira, inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 2 mg in 1 ml - linezolid is indicated for the treatment of nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14) ]. linezolid is indicated for the treatment of community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14) ]. linezolid is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes , or streptococcus agalactiae . linezolid has not been studied in the treatment of decubitus ulcers [see clinical studies (14) ]. linezolid is indicated for the treatment of vancomycin-resistant enterococcus faecium infections, including cases with concurrent bacteremia [see clinical studies (14

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - linezolid -

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid for oral suspension is indicated for the treatment of nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [ see  clinical studies (14) ].  linezolid for oral suspension is indicated for the treatment of community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [ see clinical studies (14) ]. linezolid for oral suspension is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes , or streptococcus agalactiae . linezolid for oral suspension has not been studied in the treatment of decubitus ulcers [ see clinical studies (14) ].  linezolid for oral suspensi

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - linezolid -

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

zydus lifesciences limited - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid 600 mg - linezolid tablet is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. linezolid tablet is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14) ]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14) ]. complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogen

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

celltrion, inc. - linezolid (unii: isq9i6j12j) (linezolid - unii:isq9i6j12j) - linezolid is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. linezolid is not indicated for the treatment of gram-negative infections. it is critical that specific gram-negative therapy be initiated immediately if a concomitant gram-negative pathogen is documented or suspected [see warnings and precautions (5.4) ]. nosocomial pneumonia caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates) or streptococcus pneumoniae [see clinical studies (14) ]. community-acquired pneumonia caused by streptococcus pneumoniae , including cases with concurrent bacteremia, or staphylococcus aureus (methicillin-susceptible isolates only) [see clinical studies (14) ]. complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus pyogenes , or strept